Correction: Are Glucagon-Like Peptide‑1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review

Correction: Are Glucagon-Like Peptide‑1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review

Saved in:

Bibliographic Details
Main Authors:	Juliana West, Maggie Li, Sabrina Wong, Gia Han Le, Kayla M. Teopiz, Kyle Valentino, Christine E. Dri, Roger S. McIntyre
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2025-06-01
Series:	Neurology and Therapy
Online Access:	https://doi.org/10.1007/s40120-025-00758-2
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review
by: Juliana West, et al.
Published: (2025-04-01)

Perioperative Practice Patterns of Anaesthesiologists Surrounding Glucagon-Like Peptide-1 (GLP-1) Agonist Medications
by: Meghan Brennan, et al.
Published: (2025-04-01)

Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
by: Dan Xu, et al.
Published: (2022-01-01)

Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment?
by: Lampros Chrysavgis, et al.
Published: (2025-06-01)

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cardiometabolic protection: historical development and future challenges
by: Francisco Westermeier, et al.
Published: (2025-01-01)

Correction: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cardiometabolic protection: historical development and future challenges
by: Francisco Westermeier, et al.
Published: (2025-03-01)

What Are the Experiences, Views and Perceptions of Patients, Carers and Clinicians of Glucagon‐like Peptide‐1 Receptor Agonists (GLP‐1 RAs)? A Scoping Review
by: Sam Febrey, et al.
Published: (2025-04-01)

Adverse effects of GLP – 1 Receptor Agonists
by: Anna Kasprzak, et al.
Published: (2025-02-01)

The dual GLP-1/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk
by: M. Pilar Valdecantos, et al.
Published: (2024-11-01)

A once-daily GLP-1/GIP/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans
by: Brian Finan, et al.
Published: (2025-06-01)

GLP‐1 Agonists for Pediatric Psychopharmacology: Opportunities and Cautions
by: Michael Bartkoski, et al.
Published: (2025-06-01)

REBOUND OBESITY AFTER GLP-1 AGONISTS DISCONTINUATION
by: Zainab M. Al-Shammaa, et al.
Published: (2025-07-01)

Holding GLP-1 Agonists Prior to Elective Procedures
by: Patient Safety Authority
Published: (2023-12-01)

Nephroprotective potential of glucagon-like peptide-1 receptor agonists
by: Minara S. Shamkhalova, et al.
Published: (2020-04-01)

Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
by: Richard J. MacIsaac, et al.
Published: (2024-10-01)

Glucagon-Like Peptide-1 (GLP-1) during Ramadan: Narrative Review of the Published Literature
by: Khalid Mohammed Alayed
Published: (2023-01-01)

GLP-1 Receptor Agonists’ Impact on Fertility - A Review
by: Joanna Wojda, et al.
Published: (2025-02-01)

A Closer Look at the Dermatological Profile of GLP-1 Agonists
by: Calista Persson, et al.
Published: (2025-04-01)

Relevance of Glucagon-Like Peptide 1 (GLP-1) in Inflammatory Bowel Diseases: A Narrative Review
by: Antonietta Gerarda Gravina, et al.
Published: (2025-05-01)

Glucagon-like peptide-1 receptor agonists: Prospects for use in rheumatology
by: Е. L. Nasonov, et al.
Published: (2024-04-01)

Therapeutic strategies, consequences and prospects of glucagon-like peptide-1 agonists
by: N.M. Bobok
Published: (2025-05-01)

A Comprehensive Review on the Pharmacokinetics and Drug&minus;Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist
by: Min JS, et al.
Published: (2025-04-01)

Is Weight Loss the Main Driver for A1C Improvement by Glucagon‐Like Peptide 1 (GLP‐1) Receptor Agonists? A 2.5‐Year Analysis in Real‐World Clinical Practice
by: Marwa Al‐Badri, et al.
Published: (2025-01-01)

Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective
by: Jorge Rico-Fontalvo, et al.
Published: (2024-11-01)

Retinal Pigment Epithelial Cells Express a Functional Receptor for Glucagon-Like Peptide-1 (GLP-1)
by: Alessandra Puddu, et al.
Published: (2013-01-01)

Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
by: Rui Salvador, et al.
Published: (2025-03-01)

Advances in GLP-1 receptor agonists for pain treatment and their future potential
by: Yongtao He, et al.
Published: (2025-02-01)

GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation
by: Giulia Migliorisi, et al.
Published: (2025-07-01)

GLP-1 receptor agonist therapy and pregnancy: Evolving and emerging evidence
by: Maria S Varughese, et al.
Published: (2025-03-01)

The hidden impact of GLP‐1 receptor agonists on endometrial receptivity and implantation
by: Alberto Sola‐Leyva, et al.
Published: (2025-02-01)

The new era of aspiration risk: The dilemma of GLP-1 receptor agonists
by: Jack Madden, et al.
Published: (2024-03-01)

Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland
by: Hoffmann K, et al.
Published: (2025-08-01)

Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges
by: Zhi Dong Zhou, et al.
Published: (2025-06-01)

Insights into the Efficacy of GLP-1 Agonists and Dual Agonists: Semaglutide and Tirzepatide in Obesity and Type 2 Diabetes
by: Laura Opalska, et al.
Published: (2024-12-01)

Harnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024
by: Amrutha S Alibilli, et al.
Published: (2025-07-01)

Anti-inflammatory effects of glucagon-like peptide-1 (GLP-1) in coronary artery disease: a comprehensive review
by: Alicja Skrobucha, et al.
Published: (2024-12-01)

GLP-1 and glucagon receptor dual agonism ameliorates kidney allograft fibrosis by improving lipid metabolism
by: Linjie Peng, et al.
Published: (2025-03-01)

Exploring the multifaceted roles of GLP-1 receptor agonists; a comprehensive review
by: Bisma Fatima Hammad, et al.
Published: (2025-07-01)

Hormonal modulation, mitochondria and Alzheimer’s prevention: the role of GLP-1 agonists and estrogens
by: Fernando Lizcano, et al.
Published: (2025-06-01)

Improving Reproductive Outcomes in PCOS: The Emerging Role of GLP-1 Receptor Agonists
by: Adrianna Tabeau, et al.
Published: (2025-03-01)